Daewon Pharmaceutical Co., Ltd. Overview
Daewon Pharmaceutical is a second-to-third-generation family-controlled, mid-sized Korean prescription-drug company with consolidated FY2025 revenue of KRW 605.4bn [S1]. Its franchise rests on primary-care respiratory and pain medicines sold through a dense clinic (local doctor) sales network: the Codaewon antitussive-expectorant series, the in-house new drug Pelubi (pelubiprofen, Korea's 12th domestically developed new drug), and the Colday squeezable OTC cold-syrup range. The company is attempting a three-way pivot: (1) from seasonal respiratory products toward chronic-disease drugs (hypertension, diabetes, dyslipidaemia) via in-house combinations and co-promotions (Celltrion's Idalbi family, AstraZeneca's Symbicort); (2) from generics/incrementally modified drugs toward new chemical entities (P-CAB padoprazan in Phase 3; obesity programmes); and (3) into consumer health via acquired subsidiaries (Daewon Healthcare, SD Biotechnology). Profitability has collapsed (FY2025 operating margin 0.6%) as acquisitions, price cuts and R&D spend have offset top-line growth.
What the company does
Daewon manufactures and sells finished-dose pharmaceuticals in Korea across circulatory, respiratory, anti-infective, psychoneurological, digestive and analgesic categories, and exports to roughly 40 countries in Asia, Latin America, the Middle East, CIS and Africa [S31]. The company describes itself as a "pure therapeutic medicines" company founded on the corporate philosophy of "realising human health", producing more than 200 therapeutic products sold through a nationwide sales network [S33]. It now positions itself as a "comprehensive healthcare company" spanning prescription drugs (ETC), over-the-counter drugs (OTC), health functional foods (HFF), medical devices and cosmetics [S33][S14].
Company's own description (paraphrased from IR and corporate materials)
-
Leading position in Korea's respiratory prescription market, with the No.1 antitussive-expectorant (Codaewon S) and the No.1 NSAID by prescriptions since 2018 (Pelubi family) [S19].
-
Business evolution framed as "ETC → OTC → CHC (consumer healthcare) → cosmetics" [S19].
-
Strategic emphasis on expanding chronic-disease share and reducing seasonality [S21][S9].
Independent characterisation
Daewon is best understood as a primary-care commercial engine with a narrow profit pool. Roughly 87–90% of revenue is pharmaceuticals [S2][S1]; within that, respiratory and analgesic products (≈38% of FY2025 revenue combined) are highly exposed to (a) seasonal respiratory disease incidence and (b) Korean health-insurance price regulation. The company's competitive moat is its clinic-level sales reach (historically claimed as ~one-third of Korean local clinic transactions [S34]) and its large liquid/syrup manufacturing capacity at the Jincheon smart factory, which allowed it to capture share during the 2022–2024 pandemic/endemic cough-medicine surge [S35]. The moat is weaker on the innovation side: its only approved NCE (Pelubi, 2007) has lost patent exclusivity in practice and took a 47% reimbursement price cut in May 2026 [S36].
Business and revenue model
| Revenue model component | Description | Indicative weight |
|---|---|---|
| Own-manufactured prescription products | Generics, incrementally modified drugs (IMDs), combinations, one NCE (Pelubi); sold to clinics/hospitals via wholesalers and pharmacies | Majority of the pharma segment |
| In-licensed / co-promoted products ("merchandise") | AstraZeneca Symbicort/Pulmicort (distribution and sales, royalty-bearing), Celltrion Idalbi family (co-sales) | Rising; drives cost-of-goods inflation [S37][S20] |
| OTC brands | Colday (cold), Potagel (antidiarrhoeal), pain/OTC liquids | OTC revenue >KRW 40bn annually (company claim, Sept 2025) [S19] |
| Health functional foods | Daewon Health brand B2C (Kkuljam Shot, Hair Collagen 3X, Albumin King etc.) plus contract manufacturing at Daewon Healthcare | FY2025 KRW 36.1bn segment revenue [S1] |
| Cosmetics | SD Biotechnology mask packs (≈79%) and eye patches (≈21%) | FY2025 KRW 30.1bn [S1][S38] |
| Licensing / subscription | No material licensing-out income disclosed | Not material |
Customer types: clinics and hospitals (prescribers), community pharmacies, pharmaceutical wholesalers, home-shopping and online channels (HFF), ODM customers (Daewon Healthcare), export distributors.
Value-chain position: integrated developer–manufacturer–marketer; limited API manufacturing (not disclosed); relies on outsourced APIs and in-licensed finished products for part of the portfolio.
End-markets: Korean outpatient prescription market (primary-care), Korean OTC and HFF retail, export markets (~4–6% of revenue).
Strategy
Stated strategic themes (paraphrased)
- Become a top-tier pharma company via new growth businesses and R&D (Vice Chairman's long-standing framing) [S91].
KRW 1 trillion revenue: originally targeted for 2025 when Baek In-hwan took office [S54]; recruitment-research summaries now cite a 2028 date [S73] (the revised date is not confirmed in a filing).
Chronic-disease pivot: raise circulatory/endocrine share of revenue to 35% by 2028 (from the 2024 baseline), led by the Idalbi family and in-house combinations [S21].
From generic leader to innovator: second in-house new drug (padoprazan) as the next growth engine [S40].
Consumer healthcare build-out: (HFF and cosmetics) to reduce seasonality [S9].
2H26 priorities: continue chronic-disease and HFF diversification while pursuing cost efficiencies to restore profitability [S6].
Initiatives in the last 24 months
| Initiative | Date | Detail | Source |
|---|---|---|---|
| AstraZeneca inhaler partnership | Feb 2025 | Distribution/marketing/sales of Symbicort and Pulmicort Respules; royalty terms confidential | [S37] |
| Pelubi life-cycle defence | Jan 2025 | Pelubi S launch | [S57] |
| P-CAB Phase 3 programme | Oct 2025–Jan 2026 | ERD and NERD Phase 3; H. pylori combination Phase 1 | [S62][S92] |
| Celltrion Idalbi co-promotion | Jan 2026 | Three hypertension products | [S20] |
| Twinclo launch | Apr 2026 (planned) | Own triple hypertension combination | [S21] |
| Obesity R&D | 2025–2026 | Quadruple agonist (ADA 2026), oral semaglutide (human trials planned 2027), DW-1022 patch | [S63][S88] |
| Corporate venture capital | 2026 (planned) | CVC to invest in digital-healthcare companies | [S28] |
| Subsidiary restructuring | 2025–2026 | SD Biotech 60% capital reduction (par KRW 500→200), HFF plant sale, Magok building purchase, CEO change | [S93][S85][S53] |
| Sinbaro in-sourcing | Sep 2026 | In-house production to unify production and sales | [S25] |
| ESG | 2,025 | KCGS A rating; ISO 14001 / ISO 37001; ESG committee | [S60] |
| Shareholder returns | 2024–2026 | Pay ≥15% of separate net income as dividends for 2024–2026; articles amended for dividend predictability | [S58] |
Medium-term targets / guidance
No formal numerical earnings guidance was found. Quantified targets: 35% chronic-disease revenue share by 2028 [S21]; 12 blockbuster products (KRW 10bn+ each) — achieved by 2024 per the KIR technical report [S94]; net-zero by 2050 with 40% GHG reduction by 2040 (secondary source) [S73].
Products & Services
Pricing is governed by Korea's National Health Insurance reimbursement ceiling for prescription drugs; OTC/HFF pricing is not disclosed.
Pharmaceuticals — Respiratory
| Product | Description / composition | Target | Launch / status | Key data |
|---|---|---|---|---|
| Codaewon Forte (코대원포르테) | Antitussive-expectorant suspension (dihydrocodeine-containing combination; ammonium chloride variant of Codaewon) | Acute bronchitis/cough, primary care | Mid-2010s | Codaewon series Rx KRW 56.6bn (2022), 80.4bn (2023), 93.2bn (2024) [S19] |
| Codaewon S syrup (코대원에스) | Korea's first five-component antitussive-expectorant combination; Phase 3 superiority trial vs active control | Cough/sputum | 2,020 | Rx KRW 34.3bn (2022), 51.9bn (2023), 70.1bn (2024) [S46] |
| Codaewon Plus tab (코대원플러스정) | Codaewon + Pelargonium sidoides extract | Acute bronchitis | Approved Sep 2025; launch targeted Dec 2025 | Fourth Codaewon line extension [S69] |
| Privitus suspension (프리비투스현탁액) | Antitussive (levodropropizine-class) | Cough | Pouch re-production; supply resumed Oct 2026 | Combined with Codaewon S/Forte >KRW 100bn Rx, ~42% of a ~KRW 240bn cough-syrup market (2024) [S46][S25] |
| Comfona Compact Air (콤포나콤팩트에어) | Fluticasone propionate/salmeterol DPI | Asthma/COPD | 2,020 | Own inhaler in a ~KRW 130bn inhaler market [S47] |
| Symbicort Turbuhaler/Rapihaler (AZ) | Budesonide/formoterol | Asthma, severe COPD | Distribution from Feb 2025 | 2024 Korea Rx KRW 17.7bn (company IR) [S19][S37] |
| Pulmicort Respules (AZ) | Budesonide nebuliser | Paediatric asthma, croup | Distribution from Feb 2025 | 2024 Korea Rx KRW 8.3bn; 3-year CAGR 55% (2022–24) [S19][S37] |
Pharmaceuticals — Pain / anti-inflammatory / musculoskeletal
| Product | Description | Target | Launch | Key data |
|---|---|---|---|---|
| Pelubi tab (펠루비정) | Pelubiprofen 30mg NSAID; Korea's 12th domestic new drug | Osteoarthritis, RA, back pain, fever/acute upper respiratory pain | Approved Sep 2007; launched Oct 2008 | Pelubi family Rx KRW 41.2bn (2022), 47.5bn (2023), 62.2bn (2024), 57.2bn (2025) [S19][S36]. Ceiling price cut KRW 180→96 (−46.7%) from 1 May 2026 [S36] |
| Pelubi SR (펠루비서방정 / CR) | Sustained-release pelubiprofen | Chronic pain | — | Price cut KRW 304→234 (−23.0%) from 1 May 2026 [S36] |
| Pelubi S tab (펠루비에스정) | Life-cycle extension of Pelubi | Pain | Jan 2025 | Defensive line extension [S57] |
| Sinbaro (신바로) | Natural-product osteoarthritis drug | Osteoarthritis | Daewon in-house production from Sep 2026 | 3Q25 sales KRW 5.6bn, +32.3% YoY [S66][S25] |
| Pinecue Naproxen / Pinecue Ibuprofen syrup | OTC analgesics | Consumer pain/fever | 2024–2025 | — |
Pharmaceuticals — Circulatory & endocrine (chronic disease)
| Product | Description | Target | Launch | Key data |
|---|---|---|---|---|
| Idalbi (이달비정) — Celltrion Pharm | Azilsartan medoxomil ARB | Hypertension | Co-sales from Jan 2026 | Co-promotion [S20] |
| Idalbi Clo (이달비클로정) | Azilsartan + chlorthalidone | Hypertension | Co-sales from Jan 2026 | [S20] |
| Idaldipine (이달디핀정) | Azilsartan + amlodipine IMD combination | Hypertension | Launched Jan 2026; high-dose strengths reimbursed Feb 2026 | Lead product in ~KRW 2.5trn Korean hypertension market [S20][S21][S71] |
| Twinclo (트윈클로) | Telmisartan + amlodipine + chlorthalidone (triple) | Hypertension | Planned April 2026 | Own-developed [S21] |
| Dapacita-M SR (다파시타엠서방정) | Dapagliflozin + sitagliptin + metformin (triple) | Type 2 diabetes | 2,023 | [S72] |
| Tabarozet (타바로젯) | Pitavastatin + ezetimibe | Dyslipidaemia | — | 3Q25 sales KRW 4.9bn, +30.9% YoY [S66] |
| Tizipenon (티지페논정) | Hypertriglyceridaemia agent | Hypertriglyceridaemia | — | [S73] |
| Uptava SR (업타바서방정) | — | — | Jun 2026 | [S74] |
Pharmaceuticals — Digestive
| Product | Description | Target | Launch | Key data |
|---|---|---|---|---|
| Potagel suspension (포타겔현탁액) | Antidiarrhoeal (dioctahedral smectite class) | Diarrhoea | Long-standing | Reported sales-volume No.1 for five consecutive years (company PR, 2025) [S74] |
| Pancreone tab 25000 (판크라원정) | Pancreatin 400mg enteric film-coated tablet; 25,000 EP lipase units; 23.7% smaller than equivalent capsules | Pancreatic exocrine insufficiency | 19 Oct 2026 | First tablet in a capsule-dominated Korean category [S26] |
| The Brew gel (더브루겔액) | Squeezable anti-flatulent | OTC digestive | Oct 2026 | [S25] |
OTC / Consumer health
| Product | Description | Target | Launch | Key data |
|---|---|---|---|---|
| Colday series (콜대원 콜드/코프/노즈/키즈/나이트) | Squeezable stick-pack cold syrups (acetaminophen-based and symptom variants) | Consumers, children | 2015 (10th anniversary 2025) | ~KRW 30bn brand; Colday Kids KRW 9.2bn in 2022, No.1 children's cold medicine [S75][S76]; OTC division >KRW 40bn (2025) [S19] |
| New Vein (뉴베인액) | OTC liquid (vein/circulation) | Consumers | — | Wholesale 7-pack added 2025 [S74] |
| Curevan Foam Ag (큐어반 폼 Ag) | Silver foam wound dressing | Wound care | — | [S74] |
Health functional foods (Daewon Health / Daewon Healthcare)
| Product / business | Description | Key data |
|---|---|---|
| Kkuljam Shot (꿀잠샷) | Sleep-support HFF | Driver of 1H26 HFF revenue KRW 20.7bn [S6] |
| Hair Collagen 3X (모발콜라겐3X) | Hair/skin HFF | Driver of 1H26 HFF growth [S6] |
| Albumin King / Amino King / Magnesium King | Liquid nutrition products | Albumin King sold out five consecutive home-shopping slots (2025) [S9]; Magnesium King launched Sep 2026 [S25] |
| The Collagen 100, Astarooji (eye health), PDRN dual package | HFF line extensions | Launched Jan 2026, Jan 2026, Sep 2026 [S74][S62][S32] |
| Jangdaewon Nature Plus (장대원) | Organic-certified probiotic | Exported to Hong Kong, Singapore, Philippines (2019) [S77] |
| Daewon Healthcare contract manufacturing | ODM/OEM HFF manufacturing | Company claims KRW 71.0bn contract-manufacturing revenue in 2024 [S19] — inconsistent with KRW 28.1bn consolidated HFF segment revenue; classification not reconciled |
Cosmetics (SD Biotechnology)
| Product line | Share of 2Q26 SD Biotech revenue | Notes |
|---|---|---|
| Mask packs (SNP-heritage brands) | 79% | Core line [S38] |
| Eye patches | 21% | [S38] |
Financial Narrative
Income statement
Revenue CAGR: FY2021–FY2025 4-year CAGR = 14.3%; FY2022–FY2025 3-year CAGR = 8.1% (computed).
Commentary. The five-year record has three distinct phases. (1) Pandemic/endemic surge (FY2021–FY2022): respiratory demand, Jincheon capacity and Colday OTC growth drove a 35% revenue jump in FY2022 and peak operating margin of 9.0%. (2) Diversification drag (FY2023–FY2024): revenue kept growing (+10%, +13.5%) helped by the 2023 reimbursement re-evaluation that restricted loxoprofen and pushed prescribers to Pelubi [S36], but margins compressed as Daewon Healthcare and then SD Biotech were consolidated and R&D rose. (3) Profit collapse (FY2025): revenue growth stalled (+1.2%), cost of sales rose KRW 21.8bn to KRW 332.6bn as lower-margin in-licensed products (AstraZeneca inhalers) entered the mix, SG&A rose KRW 8.4bn to KRW 245.5bn, and R&D expense rose to KRW 23.8bn [S1]. Operating income fell 87.6% to KRW 3.5bn and the company recorded a net loss for the first time in decades [S1]. The 3Q25 consolidated loss of KRW 10.4bn was the inflection low [S9].
1H26 update: revenue KRW 310.9bn (+3.1% YoY), operating income KRW 4.4bn (−45.3%), net income KRW 5.7bn (+308%, boosted by gains on disposal of investment assets) [S6]. SG&A rose 8.8% YoY owing to R&D and HFF marketing [S6]. 2Q26 was operating break-even (−KRW 9m) on revenue of KRW 152.8bn (+6.2% YoY) [S7]. Flagship Pelubi and Codaewon declined because of price cuts and an absent respiratory season, offset by Idalbi chronic-disease prescriptions and HFF [S6].
Balance sheet
Source: [S3 Valueline, DART-derived consolidated statements]. Borrowings exclude lease liabilities. Net debt = total borrowings − cash − short-term financial assets (computed). FY2025 borrowings comprise short-term borrowings 89.1, short-term bonds/CP 16.7, current portion of long-term debt 11.3, straight bonds 30.0, exchangeable bonds 15.0 and long-term borrowings 37.9 [S3].
30 June 2026: total assets 573.3; cash 23.7; short-term financial assets 43.0; total borrowings 186.6 (short-term borrowings 89.1, current portion of long-term debt 38.0, exchangeable bonds 15.2, long-term borrowings 44.3); equity 275.7; net debt ≈119.9 [S3]. The jump in the current portion (11.3 → 38.0) indicates the KRW 30bn straight bond has moved inside 12-month maturity — roughly two-thirds of gross debt is now short-dated.
Commentary. Gross debt rose 73% in three years (FY2022–FY2025) as the company funded the SD Biotech acquisition, loans to subsidiaries, the Magok building purchase and capex. The liability-to-equity ratio climbed from 82.3% (FY2022) to 105.0% (FY2024) [S10][S5] and 123.5% (FY2025, computed from [S3]; DS reports 143.6% and Valueline's indicator page 127.5% — definitional discrepancy). Borrowing dependence was ~31% of assets in FY2024 [S81]. Inventory reduction in FY2025 (−KRW 15.4bn) supported cash generation.
Cash flow
Sources: OCF FY2022–FY2024 [S4 Paasa]; FY2025 KRW 42.3bn OpenDART-verified [S80] (Paasa shows 43.6). Discrepancy: Kyobo shows FY2022 OCF of KRW 26bn vs Paasa 33.3 [S12]. Capex from DS [S10]; Valueline shows FY2025 PP&E additions of KRW 29.8bn plus intangible additions (largely capitalised development) of KRW 12.3bn [S3] — on that broader definition FY2025 FCF was ~KRW 0.2bn, and Valueline's own FCF metric is −KRW 4.7bn. Dividends: FY2022–FY2024 totals from [S58]; FY2025 from cash paid in 1H26 (KRW 5.35bn) [S3]. No buybacks identified; treasury shares carried at KRW 15.1bn (unchanged FY2022–FY2025) [S3]. D&A FY2025: depreciation KRW 18.7bn, amortisation KRW 5.1bn [S3].
1H26 note: TTM operating cash flow to June 2026 fell to KRW 18.2bn as working-capital movements reversed [S3].
Ratios
Sources: ROE [S10 DS] (Valueline shows FY2025 ROE −0.5%); all other ratios computed from [S3] balance sheet and [S4][S1] income data using year-end balances. FY2021 ROE was 3.2% [S79].
Interest coverage: FY2025 operating income / interest expense = 3.5 / 7.2 = 0.5x [S3]; TTM June 2026 ≈ 0.0x. ROIC: Kyobo shows 11.9% (FY2022) and 9.8% (FY2023) [S12]; Valueline shows −1.6% (FY2025) [S3].
Ratio commentary. Every return metric has deteriorated for three consecutive years. Coverage below 1x in FY2025 and TTM means operating profit no longer covers interest; liquidity is being supported by operating cash flow, asset sales (investment disposals in 1H26) and refinancing. The cash conversion cycle improved in FY2025 on inventory reduction, but at ~120 days remains long, reflecting syrup/seasonal stock and in-licensed product inventory.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Business | Daewon stake | Acquired | Notes |
|---|---|---|---|---|
Daewon Healthcare (대원헬스케어, ex-Kukdong H-Pharm) | HFF contract manufacturing (ODM/OEM), Yesan, South Chungcheong | 83.5% at acquisition | May 2021 (KRW 14.1bn) | KRW 0.3bn impairment reversal recognised in FY2025 [S48] |
SD Biotechnology (에스디생명공학, KOSDAQ 217480) | Cosmetics (mask packs, eye patches); HFF production division sold, treated as discontinued | 72.9% | Dec 2023 (KRW 40.0bn) | Trading suspended since Mar 2023; KRX delisting decision Oct 2026, under injunction [S53][S38] |
Daewon Meditech (ex-Delight) | Hearing aids | — | 2011 | Effectively wound down; assets KRW 44 thousand, zero revenue in 2023 [S41] |
“—” = not publicly disclosed.
Revenue by Segment and Revenue by Segment (%)
| Segment (KRW Bn) | FY2024 | FY2025 |
|---|---|---|
Pharmaceuticals revenue (KRW Bn) | 536.1 | 542.9 |
Health functional foods revenue (KRW Bn) | 28.1 | 36.1 |
Cosmetics revenue (KRW Bn) | 34.5 | 30.1 |
Consolidated revenue (KRW Bn) | 598.2 | 605.4 |
Pharmaceuticals share of consolidated revenue (%) | 89.6 | 89.7 |
HFF share of consolidated revenue (%) | 4.7 | 6.0 |
Cosmetics share of consolidated revenue (%) | 5.8 | 5.0 |
Revenue by Segment
| Therapeutic area (KRW Bn) | FY2024 | FY2025 |
|---|---|---|
Respiratory | 114.7 | 122.7 |
Antipyretic / analgesic / anti-inflammatory | 112.4 | 110.4 |
Circulatory and endocrine (chronic) | 127.4 | 123.3 |
Digestive | 50.7 | 52.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Metric (KRW Bn) | FY2024 |
|---|---|
Separate (parent) operating income (KRW Bn) | 40.9 |
Consolidated subsidiaries operating income (KRW Bn) | -12.9 |
Consolidated operating income (KRW Bn) | 28.2 |
Results by Segment (FY2021–FY2025)
| SD Biotechnology metric (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 124.7 | 92.9 | 46.9 | 34.5 | 30.1 |
Operating income (KRW Bn) | -34.8 | -41.0 | -13.7 | -9.2 | -6.3 |
Net income (KRW Bn) | -45.1 | -75.0 | -6.0 | -14.8 | -7.5 |
Quarter Metric Details
| Quarter metric (KRW Bn) | 1Q25 | 2Q25 | 3Q25 | 4Q25 | 1Q26 | 2Q26 |
|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 157.8 | 143.9 | 143.9 | 159.8 | 158.1 | 152.8 |
Operating income (KRW Bn) | 9.4 | -1.4 | -10.4 | 5.8 | 4.4 | 0.0 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 354.2 | 478.9 | 527.0 | 598.2 | 605.4 |
Revenue growth YoY (%) | 14.9 | 35.2 | 10.0 | 13.5 | 1.2 |
Gross profit (KRW Bn) | 176.5 | 237.9 | 254.2 | 287.3 | 272.8 |
Operating income (KRW Bn) | 19.4 | 43.0 | 32.2 | 28.2 | 3.5 |
EBITDA (KRW Bn) | 37.0 | 62.0 | 50.0 | 48.0 | 30.0 |
Net income consolidated (KRW Bn) | 6.6 | 30.7 | 23.5 | 9.0 | -4.0 |
Net income attributable to parent (KRW Bn) | 7.2 | 31.9 | 23.9 | 14.2 | -1.4 |
EPS basic (KRW) | 329 | 1,454 | 1,078 | 634 | -62 |
Gross margin (%) | 49.8 | 49.7 | 48.2 | 48.0 | 45.1 |
Operating margin (%) | 5.5 | 9.0 | 6.1 | 4.7 | 0.6 |
EBITDA margin (%) | 10.4 | 12.9 | 9.5 | 8.0 | 5.0 |
Net margin (%) | 1.9 | 6.4 | 4.5 | 1.5 | -0.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (KRW Bn) | 453.6 | 508.0 | 583.4 | 613.7 |
Cash and cash equivalents (KRW Bn) | 27.0 | 30.0 | 17.1 | 47.2 |
Short-term financial assets (KRW Bn) | 20.4 | 0.2 | 29.3 | 29.9 |
Short-term debt incl. current portion and short-term bonds (KRW Bn) | 63.4 | 110.6 | 120.7 | 117.1 |
Long-term debt incl. bonds (KRW Bn) | 52.1 | 34.6 | 63.6 | 82.9 |
Total borrowings (KRW Bn) | 115.5 | 145.2 | 184.3 | 200.0 |
Net debt (KRW Bn) | 68.1 | 115.0 | 137.9 | 122.9 |
Total liabilities (KRW Bn) | 204.8 | 243.7 | 298.8 | 339.1 |
Total equity (KRW Bn) | 248.8 | 264.3 | 284.6 | 274.6 |
Equity attributable to parent (KRW Bn) | 250.9 | 266.2 | 275.3 | 265.9 |
Goodwill (KRW Bn) | 11.3 | 7.3 | 5.5 | 6.0 |
Total intangibles incl. goodwill (KRW Bn) | 40.1 | 41.5 | 54.8 | 62.5 |
Capitalised development costs (KRW Bn) | 15.1 | 18.1 | 20.1 | 25.8 |
Inventories (KRW Bn) | 91.8 | 105.1 | 113.2 | 97.8 |
Trade receivables (KRW Bn) | 62.5 | 70.6 | 73.4 | 77.1 |
Working capital (current assets less current liabilities) (KRW Bn) | 79.2 | 26.6 | 56.8 | 40.3 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Operating cash flow (KRW Bn) | 33.3 | 51.7 | 30.0 | 42.3 |
Capex PP&E (KRW Bn) | 8.0 | 12.0 | 34.0 | 34.0 |
Free cash flow OCF less PP&E capex (KRW Bn) | 25.3 | 39.7 | -4.0 | 8.3 |
Cash dividends declared for the fiscal year (KRW Bn) | 7.3 | 6.4 | 6.4 | 5.4 |
Share buybacks (KRW Bn) | 0.0 | 0.0 | 0.0 | 0.0 |
Margin Analysis (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE (%) | 13.6 | 9.2 | 5.2 | -1.9 |
ROA year-end assets (%) | 6.8 | 4.6 | 1.5 | -0.7 |
Current ratio (%) | 161.8 | 114.6 | 128.3 | 118.6 |
Total borrowings to equity (%) | 46.4 | 54.9 | 64.8 | 72.8 |
Total liabilities to equity (%) | 82.3 | 92.2 | 105.0 | 123.5 |
Net debt to EBITDA (x) | 1.1 | 2.3 | 2.9 | 4.1 |
Asset turnover (x) | 1.06 | 1.04 | 1.03 | 0.99 |
Days sales outstanding (days) | 47.6 | 48.9 | 44.8 | 46.5 |
Days inventory outstanding (days) | 139.0 | 140.6 | 132.9 | 107.3 |
Days payables outstanding (days) | 29.7 | 28.0 | 24.5 | 33.2 |
Cash conversion cycle (days) | 156.9 | 161.5 | 153.2 | 120.6 |
Revenue by Region (%)
| Geographic metric | FY2021 | FY2023 | FY2025 |
|---|---|---|---|
Overseas share of revenue (%) | 2.87 | 2.00 | 4.29 |
Share Price and Market Valuation
| Price metric (KRW) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 18,750 | 15,660 | 14,250 | 11,950 |
Year-end market capitalisation (KRW Bn) | 411.8 | 347.5 | 319.6 | 268.0 |
Valuation Snapshot
| Multiple | Value | Source / basis |
|---|---|---|
P/E (TTM) | 66.9–69.5x | [S3][S121] |
P/B | 0.65–0.67x | [S3][S121] |
P/S (TTM) | 0.29x | [S3] |
EV/EBITDA (TTM Jun 2026) | 7.6x | [S3] |
EV/Sales (TTM) | ~0.49x (EV ≈ KRW 304bn: mkt cap 175.6 + net debt 119.9 + minorities 8.1; TTM revenue 614.6) | Computed from [S3] |
Forward P/E (12m) | ~12.0x | [S2] |
Analyst Ratings & Targets
| Broker | Date | Rating | Target price (KRW) | Key view |
|---|---|---|---|---|
Consensus (5 brokers) | Oct 2026 | — | 14,800 | — |
DS Investment & Securities | 26 May 2026 | Buy (initiation) | 16,000 | FY2026E revenue 627.2bn, OP 19.4bn, EPS 756; Idalbi family to drive growth |
SK Securities | 19 May 2026 | Buy | 15,000 | Subsidiary losses narrowing; R&D optionality |
Kiwoom Securities | 28 Jan 2026 | Buy | 15,000 (cut 11.8%) | Subsidiary turnaround needed |
Kyobo Securities | 17 May 2024 | Buy | 20,000 | Historic reference |
Dividend metric
| Dividend metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Dividend per share (KRW) | 300 | 300 | 250 |
Analyst Conclusions
Guidance and expectations
Management has given qualitative guidance only: diversify into chronic disease and HFF while improving profitability through cost efficiency in 2H26 [S6]. Sell-side FY2026 expectations: DS revenue KRW 627.2bn (+3.6%) and OP KRW 19.4bn [S10]; SK Securities had earlier projected FY2026 OP of ~KRW 31.4bn [S9], since tempered by a 1Q26 miss [S8]. 1H26 delivered only KRW 4.4bn of OP, so FY2026 consensus appears to require a strong 4Q respiratory season.
Bull case
-
Chronic pivot gains traction: Idalbi family and Twinclo, plus Tabarozet/Sinbaro growth (+30%+ in 3Q25), lift circulatory/endocrine toward 35% of sales by 2028 and dampen seasonality [S21][S66].
-
Padoprazan approval (ERD/NERD Phase 3 in parallel) would give Daewon a second proprietary drug in a ~KRW 400bn P-CAB market [S62][S32].
-
Deep value with optionality: 0.66x P/B and 7.6x EV/EBITDA with ~3% yield; obesity assets (quadruple agonist) demonstrated the market will pay for credible data (June 2026 limit-up) [S3][S107].
Bear case
-
Structural margin damage: Pelubi's price cut plus 10 pelubiprofen competitors and the sector generic reform hit two of Daewon's three pillars simultaneously [S36][S109][S106].
-
Balance-sheet strain: interest cover <1x, debt ratio >120%, two-thirds of debt short-dated; SD Biotech may require more cash despite delisting [S3][S53].
-
Execution record: two diversification deals have destroyed value; co-promotion growth carries lower gross margins (FY2025 cost of sales +7%) [S41][S1].
Key catalysts and monitorables (next 12 months)
-
3Q26 results (mid-Nov 2026) and 4Q26 respiratory season strength.
-
Court ruling on SD Biotech's delisting injunction and any further Daewon funding.
-
Padoprazan ERD/NERD Phase 3 enrolment progress and topline timing.
-
Pelubi volume retention post price cut; pace of second-wave generic launches.
-
Idalbi/Idaldipine and Twinclo prescription ramps (UBIST monthly data).
-
Implementation details of the generic-price reform for Daewon's portfolio; any R&D-intensity premiums.
-
CVC establishment and investments; refinancing of the straight bond.
-
FY2026 dividend (policy floor of 15% of separate NI).
Analyst verdict
Daewon Pharmaceutical is a capable commercial organisation trapped in a weak profit structure. Its core competence — a primary-care salesforce plus syrup manufacturing scale — produced a genuine growth story between 2021 and 2024, lifting revenue from KRW 354bn to KRW 598bn. That story has now been interrupted from three directions at once. First, regulation: the Pelubi price cut and the generic-price reform reduce the value of exactly the kind of portfolio Daewon owns. Second, capital allocation: SD Biotechnology has absorbed KRW 60bn of acquisition and asset-purchase capital while shrinking and moving toward delisting, and consolidated losses there have turned a solidly profitable parent into a break-even group. Third, mix: growth is increasingly coming from in-licensed products (AstraZeneca, Celltrion) that carry thinner margins, so revenue gains no longer translate into profit.
The valuation already reflects much of this — the shares trade at roughly two-thirds of book value, under 0.5x EV/sales and about 7.6x trailing EV/EBITDA, with a ~3% dividend yield — and the sell side remains uniformly constructive with targets near KRW 15,000. But the evidence for a turnaround is not yet in the numbers: 1H26 operating profit was only KRW 4.4bn, interest cover is below 1x, and the balance sheet has limited room for further subsidiary support.
The investment case therefore hinges on three binary-ish events over 12–24 months: a normal-to-strong respiratory season restoring the cash engine; containment of SD Biotech without further large cash calls; and padoprazan Phase 3 success. The obesity programmes are early-stage options, not value drivers. On balance, Daewon screens as a cheap but fragile special-situation. Positioning should be contingent on evidence of margin recovery in 4Q26 results.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Background |
|---|---|---|
Baek Seung-ho (백승호) | Chairman; inside director | Eldest son of founder; managed the company with his brother for ~40 years; age ~69 (2025) |
Baek Seung-yeol (백승열) | Vice Chairman; co-CEO; Chair of the Board | Born 1959; Seoul National University (agricultural biology); CEO since 1996 |
Baek In-hwan / Jonathan In Baek (백인환) | President; co-CEO (since Jan 2024); inside director | Born 1984; economics, Brandeis University; joined 2011 as deputy manager in Strategy Office; overseas business, healthcare, new growth, marketing head; president from end-2022 |
Bang Yong-won (방용원) | Outside director; Audit Committee chair | Former vice chairman, EY Hanyoung |
Lee Dong-hee (이동희) | Outside director | Vice chairman, Korea Pharmaceutical Traders Association |
Cho Joo-yeon (조주연) | Outside director | Attorney, Shin & Kim (Sejong) |
Executive Leadership Team
| Name | Role | Notes |
|---|---|---|
Baek In-yeong (백인영) | Head of Healthcare Business Division; CEO of SD Biotechnology since Nov 2025 | Vice Chairman's eldest son; joined 2019; ran OTC/HFF |
Kim Joo-il (김주일) | Vice President, R&D Division | Presented quadruple-agonist strategy |
Lee Kyung-joon (이경준) | Head of Central Research Institute (Executive Director) | Obesity pipeline timelines |
Park Jo-hyun (박조현) | Head of CHC (Managing Director) | Joined Aug 2025 from Chong Kun Dang Health |
Lee Jeong-hee (이정희) | Head of OTC (Managing Director) | — |
Major Shareholders
| Holder | Stake | As of |
|---|---|---|
Largest shareholder and related parties (Baek family et al.) | 37.69% | End-2025 |
Baek Seung-yeol | 11.58% (Dealsite) / 14.31% (IB Tomato) | Q3 2023 / early 2024 |
Baek Seung-ho | 9.84% | Q3 2023 |
Baek In-hwan | 5.93% | Q3 2023 |
Baek In-yeong | 2.98% | Sept 2023 |
Fidelity Management & Research and affiliates | 9.85% | May 2024 |
Minority shareholders (19,787 holders) | 47.85% | End-2025 |
Foreign ownership | 13.7% | Jan 2026 |
Competitive Landscape
Competitors by Segment
| Segment | Named competitors | Positioning notes |
|---|---|---|
Antitussive-expectorants | Ahn-Gook Pharmaceutical (Synatura), Yuhan Corporation (Coughu) | Daewon's Codaewon series held 63.7% of the dihydrocodeine-combination market (KRW 151.2bn total) in 2024 |
NSAIDs / pelubiprofen | Youngjin Pharm (Pelps), Huons (Peloen), Chong Kun Dang (Belupen), Donggu Bio (Pelbifen), Hana Pharm, HLB Pharm, Dasan, Alico | ~KRW 50bn pelubiprofen market; generics held ~10% share in 1Q25 |
P-CAB (pipeline) | HK inno.N (K-CAB), Daewoong (Fexuclue), Onconic Therapeutics | Padoprazan would be Korea's fourth P-CAB; market ~KRW 400bn |
Hypertension | Boryung (Kanarb family), Hanmi Pharm (Amosartan), Celltrion Pharm (partner) | Daewon is a new entrant via co-promotion |
Asthma inhalers | Kolon Pharm (Foster, Trimbow), Hanmi (Flutelol), Huons (Zephirus) | Few domestic players due to device barriers |
HFF | Chong Kun Dang Health, GC Wellbeing | Daewon is sub-scale |
Cosmetics | Dongkook Pharmaceutical (Centellian24) | Dongkook's healthcare/cosmetics >50% of revenue |
Mid-cap peer set (revenue) | Ildong Pharmaceutical, Jeil Pharmaceutical, Celltrion Pharm, Kwang Dong, Daewoong | Comparable scale or larger |
Peer Comparison FY2025
| Metric | Daewon | Celltrion Pharm (separate) | Kwang Dong | Daewoong |
|---|---|---|---|---|
Revenue (KRW Bn) | 605.4 | 536.4 | 1,659.5 | 1,570.8 |
Revenue growth YoY (%) | 1.2 | 12.2 | 1.1 | 10.4 |
Operating income (KRW Bn) | 3.5 | 56.1 | 31.0 | 196.8 |
Operating margin (%) | 0.6 | 10.5 | 1.9 | 12.5 |



